Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML

Decitabine is a DNA‐hypomethylating agent that has been widely applied for the treatment of acute myeloid leukaemia (AML) patients who are elderly or unfit for intensive therapy. Although effective, the complete response rate to decitabine is only around 30% and the overall survival remains poor. Em...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Chenchen, Jia, Bei, Wang, Ming, Schell, Todd D., Claxton, David F., Ehmann, W Christopher, Rybka, Witold B., Mineishi, Shin, Naik, Seema, Songdej, Natthapol, Sivik, Jeff M., Hohl, Raymond J., Zeng, Hui, Zheng, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy – Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065206/
https://www.ncbi.nlm.nih.gov/pubmed/31573077
http://dx.doi.org/10.1111/bjh.16228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065206/
https://www.ncbi.nlm.nih.gov/pubmed/31573077
http://dx.doi.org/10.1111/bjh.16228

Ejemplares similares